Question 1:

In the last three months, how many patients did you see in the following subgroups? Please include all patients in each subgroup, including patients not actively receiving treatment (i.e. in follow-up after treatment).

Question 2:

In the last three months, how many of your patients with metastatic or locally advanced, HR+/HER2-breast cancer received the following regimens: [free numerical response for each choice]

Question 3:

Interim data were presented at ASCO last week for the PALOMA3 trial of palbociclib+fulvestrant as second-line treatment for advanced HR+/HER2- BC: mPFS 9.2 months for palbo+fulvestrant and 3.8 months for placebo+fulvestrant. In the next 12 months, how often will you prescribe the following regimens to patients in the following lines of treatment?

Question 4:

How strongly do the following factors affect your palbociclib prescribing practices? 1=factor doesn’t affect my prescribing at all, 4=factor strongly affects my prescribing

Question 5:

The EGFR/HER2 inhibitor neratinib was tested in a Phase 3 trial in Stage 2/3 HER2+ BC: 1 yr neratinib or pbo PO QD after adjuvant treatment w/ 1 yr Herceptin. Invasive DFS are in the table. TEAEs included 40% Gr3 diarrhea; in another trial, loperamide prophylaxis reduced diarrhea to 5%. If neratinib is approved in 2017, how will you prescribe it to early BC patients in the trial population?